Atopic dermatitis (AD) is a chronic, inflammatory skin disease characterized by 
pruritus, inflammatory erythematous skin lesions, and skin-barrier defect. 
Current mainstay treatments of emollients, steroids, calcineurin inhibitors, and 
immunosuppressants have limited efficacy and potentially serious side effects. 
Recent advances and understanding of the pathogenesis of AD have resulted in new 
therapies that target specific pathways with increased efficacy and the 
potential for less systemic side effects. New FDA-approved therapies for AD are 
crisaborole and dupilumab. The JAK-STAT inhibitors (baricitinib, upadacitinib, 
PF-04965842, ASN002, tofacitinib, ruxolitinib, and delgocitinib) have the most 
promising results of the emerging therapies. Other drugs with potential include 
the aryl hydrocarbon receptor modulating agent tapinarof, the IL-4/IL-13 
antagonists lebrikizumab and tralokinumab, and the IL-31Rα antagonist 
nemolizumab. In this review, new and emerging AD therapies will be discussed 
along with their mechanisms of action and their potential based on clinical 
study data.